10.3389/fnut.2024.1421386 17 ChenW
Combination Therapies: Exploring combinations with other metabolic agents to enhance efficacy and address multiple aspects of obesity
Marathe CS, Marathe JA, Rayner CK, Kar P, Jones KL, Horowitz M (2019) Hypoglycaemia and gastric emptying
Fragranced body sprays cover the smell but leave your skin itchy or rashy
Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants